Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Gilteritinib in Pts w/ FLT3 Mutated Relapsed or Refractory AML or FLT3-Mutated AML in CR w/ MRD

Protocol: OSU-17214

Full Title

A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)

Acute Myeloid Leukemia Leukemia